CooperVision Shares New Analysis of MiSight 1 day Contact Lens Performance at ARVO 2022
Tuesday, May 3 2022 | 14 h 05 min | Events, News, Press Release
CooperVision will share new data and analysis demonstrating the performance and efficacy of its innovative MiSight® 1 day contact lens during the 2022 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver from May 1-4.
“The increasing severity and prevalence of myopia progression in children is one of the greatest healthcare issues today, with consequences that will last for generations,” said Paul Chamberlain, BSc (Hons), Director of Research Programs for CooperVision. “Our extensive scientific and commercial innovations have made it easier for eye care professionals to address this challenge and incorporate myopia management as the standard of care. The works we are presenting at ARVO build further confidence in MiSight® 1 day contact lenses* as a preferred approach.”
Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing (Meyer D, et al) presents evidence that myopia control using MiSight® 1 day contact lenses in age-appropriate children is achieved through added myopic defocus, validating prior hypotheses. The study also quantified the myopic defocus dose delivered to children in two ways: by diopters and by the proportion of light focused in front of the retina. This work was conducted with the Indiana University School of Optometry.
Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear (Hammond D, et al) offers further in-depth analysis of the seven-year MiSight® 1 day clinical trial, which is the longest-running soft contact lens study among children. The twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained.
This latest work provides a deeper dive into the year seven data. These results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18. The investigators conclude that starting MiSight® 1 day at a younger age* and continuing throughout teenage years reduces time during which untreated eye growth can occur.
Click HERE for the full press release.
